Exhaled NO predicts cyclophosphamide response in scleroderma-related lung disease

Nitric Oxide - Biology and Chemistry

Volumn 40, Issue , 2014, Pages 17-21

  Tiev, Kiet Phong ^a   Rivière, Sébastien ^b   Hua Huy, Thong ^c   Cabane, Jean ^b   Dinh Xuan, Anh Tuan ^c  

^a Site Pasteur   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cyclophosphamide; Exhaled nitric oxide; Lung fibrosis; Systemic sclerosis

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE;

ADULT; ALVEOLAR CONCENTRATION; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL LUNG DISEASE; LUNG CAPACITY; LUNG FIBROSIS; LUNG FUNCTION TEST; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; RESPIRATORY TRACT PARAMETERS; SCLERODERMA RELATED INTERSTITIAL LUNG DISEASE; TOTAL LUNG CAPACITY; TREATMENT RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; PROSPECTIVE STUDY; SCLERODERMA, SYSTEMIC;

ADMINISTRATION, INTRAVENOUS; ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 84901457455     PISSN: 10898603     EISSN: 10898611     Source Type: Journal    
DOI: 10.1016/j.niox.2014.04.011     Document Type: Article

References (29)

1. A. Gabrielli, E.V. Avvedimento, and T. Krieg T, Scleroderma N. Engl. J. Med. 360 2009 1989 2003
2. V.D. Steen, C. Conte, G.R. Owens, and T.A. Jr Medsger, Severe restrictive lung disease in systemic sclerosis Arthritis Rheum. 37 1994 1283 1289 (Pubitemid 24320744)
3. V.D. Steen, and T.A. Jr Medsger, Changes in causes of death in systemic sclerosis, 1972-2002 Ann. Rheum. Dis. 66 2007 940 944 (Pubitemid 46999798)
4. D.P. Tashkin, R. Elashoff, P.J. Clements, J. Goldin, M.D. Roth, D.E. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, J.R. Seibold, D.J. Riley, V.M. Hsu, J. Varga, D.E. Schraufnagel, A. Theodore, R. Simms, R. Wise, F. Wigley, B. White, V.D. Steen, C. Read, M. Mayes, E. Parsley, K. Mubarak, M.K. Connolly, J. Golden, M. Olman, B. Fessler, N. Rothfield, and M. Metersky Scleroderma Lung Study Research Group, Cyclophosphamide versus placebo in scleroderma lung disease N. Engl. J. Med. 354 2006 2655 2666
5. C. Nannini, C.P. West, P.J. Erwin, and E.L. Matteson Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies Arthritis. Res. Ther. 10 2008 R124
6. M.D. Roth, C.H. Tseng, P.J. Clements, D.E. Furst, D.P. Tashkin, J.G. Goldin, D. Khanna, E.C. Kleerup, N. Li, D. Elashoff, R.M. Elashoff, and Scleroderma Lung Study Research Group Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease Arthritis Rheum. 63 2011 2797 2808
7. B. Thébaud, J.F. Arnal, J.C. Mercier, and A.T. Dinh-Xuan Inhaled and exhaled nitric oxide Cell. Mol. Life Sci. 55 1999 1103 1112 (Pubitemid 29361076)
8. F.L. Ricciardolo, P.J. Sterk, B. Gaston, and G. Folkerts Nitric oxide in health and disease of the respiratory system Physiol. Rev. 84 2004 731 765 (Pubitemid 38823765)
9. V.J. Thannickal, G.B. Toews, E.S. White, J.P. Lynch 3rd, and F.J. Martinez Mechanisms of pulmonary fibrosis Ann. Rev. Med. 55 2004 395 417 (Pubitemid 38316734)
10. K.P. Tiev, J. Cabane, F. Aubourg, A. Kettaneh, M. Ziani, L. Mouthon, S. Duong-Quy, I. Fajac, L. Guillevin, and A.T. Dinh-Xuan Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Eur. Respir. J. 30 2007 26 30 (Pubitemid 47074002)
11. R.E. Girgis, M.K. Gugnani, J. Abrams, and M.D. Mayes Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease Am. J. Respir. Crit. Care Med. 165 2002 1587 1591 (Pubitemid 34693936)
12. T. Hua-Huy, K.P. Tiev, C. Chereau, S. Duong-Quy, J. Cabane, and A.T. Dinh-Xuan Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis J. Rheumatol. 37 2010 1680 1687
13. K.P. Tiev, T. Hua-Huy, A. Kettaneh, Y. Allanore, N.N. Le-Dong, S. Duong-Quy, J. Cabane, and A.T. Dinh-Xuan Alveolar concentration of nitric oxide predicts pulmonary function deterioration in scleroderma Thorax 67 2012 157 163
14. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Arthritis. Rheum. 23 1980 581 590
15. E.C. LeRoy, C. Black, R. Fleischmajer, S. Jablonska, T. Krieg, and T.A. Jr Medsger, N. Rowell, F. Wollheim, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J. Rheumatol. 15 1988 202 205 (Pubitemid 18073738)
16. M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi, and J. Wanger ATS/ERS Task Force Standardisation of spirometry Eur. Respir. J. 26 2005 319 338 (Pubitemid 41079078)
17. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors and by the ERS Executive Committee Am. J. Respir. Crit. Care Med. 165 2002 277 304
18. E.A. Kazerooni, F.J. Martinez, A. Flint, D.A. Jamadar, B.H. Gross, D.L. Spizarny, P.N. Cascade, R.I. Whyte, J.P. Lynch 3rd, and G. Toews Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring A.J.R. Am. J. Roentgenol. 169 1997 977 983 (Pubitemid 27406888)
19. P.G. Yock, and R.L. Popp Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation Circulation 70 1984 657 662 (Pubitemid 14020664)
20. V.V. McLaughlin, S.L. Archer, D.B. Badesch, R.J. Barst, H.W. Farber, J.R. Lindner, M.A. Mathier, M.D. McGoon, M.H. Park, R.S. Rosenson, L.J. Rubin, V.F. Tapson, J. Varga, R.A. Harrington, J.L. Anderson, E.R. Bates, C.R. Bridges, M.J. Eisenberg, V.A. Ferrari, C.L. Grines, M.A. Hlatky, A.K. Jacobs, S. Kaul, R.C. Lichtenberg, J.R. Lindner, D.J. Moliterno, D. Mukherjee, G.M. Pohost, R.S. Rosenson, R.S. Schofield, S.J. Shubrooks, J.H. Stein, C.M. Tracy, H.H. Weitz, and D.J. Wesley ACCF, AHA. ACCF, AHA expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society Inc, and the Pulmonary Hypertension Association Circulation 119 2009 2009 2250 2294
21. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide Am. J. Respir. Crit. Care. Med. 171 2005 912 930
22. N.M. Tsoukias, and S.C. George A two-compartment model of pulmonary nitric oxide exchange dynamics J. Appl. Physiol. 85 1998 653 666 (Pubitemid 28365835)
23. S.C. George, M. Hogman, S. Permutt, and P.E. Silkoff Modeling pulmonary nitric oxide exchange J. Appl. Physiol. 96 2004 831 839 (Pubitemid 38248651)
24. B. White, W.C. Moore, F.M. Wigley, H.Q. Xiao, and R.A. Wise Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann. Intern. Med. 132 2000 947 954 (Pubitemid 30397594)
25. A. Bérezné, B. Ranque, D. Valeyre, M. Brauner, Y. Allanore, D. Launay, V. Le Guern, J.E. Kahn, L.J. Couderc, J. Constans, P. Cohen, A. Mahr, C. Pagnoux, E. Hachulla, A. Kahan, J. Cabane, L. Guillevin, and L. Mouthon Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study J. Rheumatol. 35 2008 1064 1072 (Pubitemid 351813153)
26. D.P. Tashkin, R. Elashoff, P.J. Clements, M.D. Roth, D.E. Furst, R.M. Silver, J. Goldin, E. Arriola, C. Strange, M.B. Bolster, J.R. Seibold, D.J. Riley, V.M. Hsu, J. Varga, D. Schraufnagel, A. Theodore, R. Simms, R. Wise, F. Wigley, B. White, V.D. Steen, C. Read, M. Mayes, E. Parsley, K. Mubarak, M.K. Connolly, J. Golden, M. Olman, B. Fessler, N. Rothfield, M. Metersky, D. Khanna, N. Li, G. Li, and Scleroderma Lung Study Research Group Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease Am. J. Respir. Crit. Care Med. 176 2007 1026 1034 (Pubitemid 350127847)
27. R.K. Hoyles, R.W. Ellis, J. Wellsbury, B. Lees, P. Newlands, N.S. Goh, C. Roberts, S. Desai, A.L. Herrick, N.J. McHugh, N.M. Foley, S.B. Pearson, P. Emery, D.J. Veale, C.P. Denton, A.U. Wells, C.M. Black, and R.M. du Bois A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum. 54 2006 3962 3970 (Pubitemid 44955900)
28. C. Strange, M.B. Bolster, and M.D. Roth et al. Broncho-alveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease Am. J. Respir. Crit. Care Med. 177 2008 91 98
29. M.D. Roth, C.H. Tseng, P.J. Clements, D.E. Furst, D.P. Tashkin, J.G. Goldin, D. Khanna, E.C. Kleerup, N. Li, D. Elashoff, R.M. Elashoff, and Scleroderma Lung Study Research Group Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease Arthritis. Rheum. 63 2011 2797 2808